Dan Jacob Gelvan

Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel.

Aurum Ventures MKI Ltd (Aurum Ventures) is a venture capital subsidiary of Morris Kahn founded in 1998 by Morris Kahn. The firm is headquartered in Tel Aviv, Israel.

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.

CorAssist Cardiovascular Ltd. develops therapeutic products for treating diastolic heart failure. Its proprietary technology enables the implantation of a device that directly improves cardiac diastolic function. The firm’s product, the ImCardia, is an elastic self-expanding device that is attached to the external left ventricular surface, through a simple off-pump closed heart procedure. The company was founded by Yair Feld, Yotam Reisner and Shay Dubi in 2003 and is headquartered in Haifa, Israel.

IntelliDx, Inc. develops medical devices. It offers automated ex vivo blood analysis systems that measure the constituents of flowing human blood, and automated blood glucose monitoring systems that measure glucose in hospitalized patients who have abnormally elevated sugar levels. The company was founded in 2000 and is headquartered in Santa Clara, CA.

Vecta Ltd. develops products for the gastrointestinal diseases. Its product VECAM-111 meets a well-known unmet need to address symptoms of gastroesophageal reflux disease (GERD) that are not commonly addressed by existing therapeutic options. The company develops enhanced novel drug formulation for symptomatic GERD. Vecta was founded by Yehuda Chowers and Dan J. Gelvan in 2001 and is headquartered in Ramat Gan, Israel.

FertiSeeds Ltd. develops technology for producing high yield hybrid seeds. It focuses on development of unique, state-of-the-art technologies with wide global applications and on speedy commercialization. The company was founded by Max Herzberg and Shamay Izhar in 2000 and is headquartered in Ness Ziona, Israel.

LifeBond Ltd. engages in the development of medical devices designed to restore and repair tissues to reduce post-operative complications. The company was founded by Nir Mashkif, Orahn Preiss-Bloom and Ishay Attar in 2007 and is headquartered in Caesarea, Israel.

Nephera Ltd. develops products to protect the kidneys via neuro-hormonal modulation. Its technology is based on electrical stimulation of the urinary bladder in order to improve renal function using natural mechanisms. The firm's product RenaSense, which is a medical device that improves and maintains kidney functionality in patients suffering from decompensate heart failure. The company was founded by Gill Bar-Yoseph and Yair Feld in 2008 and is headquartered in Caesarea, Israel.